Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	53.63B
Revenue (ttm)	3.98B
Net Income (ttm)	601.63M
Shares Out	1.11B
EPS (ttm)	0.54
PE Ratio	89.09
Forward PE	78.87
Dividend	0.50 (1.04%)
Ex-Dividend Date	May 14, 2025

Volume	16,171,131
Average Volume	9,677,539
Open	47.74
Previous Close	48.11
Day's Range	47.74 - 50.51
52-Week Range	27.51 - 55.48
Beta	0.46
RSI	47.82
Earnings Date	Aug 20, 2025

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiol...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 3,596
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2024, SHE:002294's revenue was 4.01 billion, an increase of 19.22% compared to the previous year's 3.37 billion. Earnings were 601.57 million, an increase of 3.71%.